1172583-76-4Relevant academic research and scientific papers
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors
Koltun, Dmitry O.,Vasilevich, Natalya I.,Parkhill, Eric Q.,Glushkov, Andrei I.,Zilbershtein, Timur M.,Mayboroda, Elena I.,Boze, Melanie A.,Cole, Andrew G.,Henderson, Ian,Zautke, Nathan A.,Brunn, Sandra A.,Chu, Nancy,Hao, Jia,Mollova, Nevena,Leung, Kwan,Chisholm, Jeffrey W.,Zablocki, Jeff
scheme or table, p. 3050 - 3053 (2010/01/16)
We discovered a structurally novel SCD (Δ9 desaturase) inhibitor 4a (CVT-11,563) that has 119 nM potency in a human cell-based (HEPG2) SCD assay and selectivity against Δ5 and Δ6 desaturases. This compound has 90% oral bioavailability (rat) and excellent
